PT - JOURNAL ARTICLE AU - Alexis Spire AU - Nathalie Bajos AU - Léna Silberzan TI - Social inequalities in hostility toward vaccination against Covid-19 AID - 10.1101/2021.06.07.21258461 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.07.21258461 4099 - http://medrxiv.org/content/early/2021/06/10/2021.06.07.21258461.short 4100 - http://medrxiv.org/content/early/2021/06/10/2021.06.07.21258461.full AB - In recent decades, France has appeared as a country particularly hostile to vaccination in general. When asked in November 2020 about the intention to take the Covid-19 vaccine, the French public showed, once again, reluctance. Therefore, France appeared as an ideal case study to analyze whether the hostility toward the Covid-19 vaccine has its own reasons or whether it is related to the reluctance to the principle of vaccination itself. Our objective was to determine the specificity of the social determinants of the intention to get the Covid-19 vaccine. Thanks to the use of a large random sample of the general population in France (86,000 individuals), the reluctant to Covid-19 vaccine could be clearly distinguished from the hesitant and the convinced, and thereby thoroughly analyzed. Our analysis highlighted a gendered reluctance toward vaccination in general but even more so regarding vaccination against Covid-19. It might refer to women being more concerned about the possible effects of an injection in their body, especially at the age of maternity and a differentiated socialization making them more sensitive than men to long-term risks and more apprehensive toward rapid technological change. We also found that people at the bottom of the social hierarchy, in terms of level of education, financial resources, and immigration status, were more likely to refuse the Covid-19 vaccine. Nevertheless, this reluctance was less prominent than for vaccination in general, reflecting the actual spread of the epidemic in various social milieux. Finally, our analysis showed that trust in the government’s actions was significantly associated with reluctance toward the Covid-19 vaccine, even more than toward vaccination in general.Specific campaigns should be thought beforehand to reach women and people at the bottom of the social hierarchy to avoid furthering social inequalities in terms of morbidity and mortality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Inserm (Institut National de la Sante et de la Recherche Medicale); the French Ministry for Research; and the DREES (Direction de la recherche, des etudes, de l'evaluation et des statistiques). The funders facilitated data acquisition but had no role in the design, analysis, interpretation, or writing. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. [101016167], ORCHESTRA (Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic). Pr. Bajos has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No. [856478]). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The survey was approved by the CNIL (French independent administrative authority responsible for data protection) on April 25th 2020 (ref: MLD/MFI/AR205138) and by the "Comite de protection des personnes" (French equivalent of the Research Ethics Committee) on April 24th. The survey also obtained an agreement from the "Comite du Label de la statistique publique", proving its adequacy to statistical quality standards.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analyzed during the current study are available from the corresponding author on reasonable request.